Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Vaccine | 1 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HIV-1 gag inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date- |
Sponsor / Collaborator |
Start Date25 May 2023 |
Sponsor / Collaborator |
Start Date14 Sep 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
SNP 7/8a | Neoplasms More | Preclinical |
VRC-HIVADV014-00-VP ( HIV-1 gag x HIV-1 pol ) | HIV Infections More | Discontinued |
VRC-HIVADV053-00-VP | HIV Infections More | Discontinued |
HIV vaccine rAd5-gag-pol VRC(GenVec) | HIV Infections More | Discontinued |
Ebola virus DNA vaccine(National Institute of Allergy & Infectious Diseases) | Hemorrhagic Fever, Ebola More | Pending |